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Osteoporosis, a disease of low bonemass, is associ-
ated with decreased osteoblast numbers and
increased levels of oxidative stress within osteo-
blasts. Since transcription factors of the FoxO family
confer stress resistance, we investigated their poten-
tial impact on skeletal integrity. Here we employ cell-
specific deletion and molecular analyses to show
that, among the three FoxO proteins, only FoxO1 is
required for proliferation and redox balance in osteo-
blasts and thereby controls bone formation. FoxO1
regulation of osteoblast proliferation occurs through
its interaction with ATF4, a transcription factor regu-
lating amino acid import, as well as through its regu-
lation of a stress-dependent pathway influencing p53
signaling. Accordingly, decreasing oxidative stress
levels or increasing protein intake normalizes bone
formation and bone mass in mice lacking FoxO1
specifically in osteoblasts. These results identify
FoxO1 as a crucial regulator of osteoblast physiology
and provide a direct mechanistic link between oxida-
tive stress and the regulation of bone remodeling.
INTRODUCTION
In adult vertebrates, bones are constantly renewed by a physio-
logical process called bone remodeling, which includes two
cellular events occurring in succession. The first one is resorp-
tion, or destruction of the mineralized bone matrix, by osteo-
clasts, and it is followed by de novo bone formation by osteo-
blasts (Harada and Rodan, 2003; Teitelbaum and Ross, 2003).
Bone remodeling is affected in the most frequent degenerative
disease of bones, osteoporosis, a low bonemass disease result-
ing from an imbalance between bone formation and resorption
(Rodan and Martin, 2000; Raisz, 2005). Starting in their mid-
40s, both men and women experience a progressive decline in
bone mass and strength (Riggs et al., 2006; Bouxsein et al.,
2006), which in women is accelerated at menopause because
of the decline of estrogens. Hence, osteoporosis can be viewed
also as a disease of aging.Cell MA growing number of evidence has linked aging and the devel-
opment of age-related diseases to increased levels of oxidative
stress, indicating that oxidative stress plays a significant role in
their pathogenesis (Finkel and Holbrook, 2000; Quarrie and Ria-
bowol, 2004). Similar to other aging-related diseases, the devel-
opment of osteoporosis has been associated with increased
levels of oxidative stress in osteoblasts, suggesting that this
may be one critical component of the pathophysiology of bone
loss (Levasseur et al., 2003; Bai et al., 2004; Lean et al., 2003; Al-
meida et al., 2007). Consistent with this idea, an osteoporotic
phenotype has been observed in mouse models of premature
aging associated with oxidative damage (Tyner et al., 2002;
De Boer et al., 2002).
Oxidative stress is the result of elevated levels of reactive
oxygen species (ROS), the most important of which are super-
oxide anions, hydroxyl radicals, and hydrogen peroxide. A rise
in the level of ROS can damage proteins, lipids, and DNA, even-
tually leading to cell death. Alternatively, it can trigger the activa-
tion of specific physiologic signaling pathways. As a matter of
fact, physiological levels of stress activate defense signaling
mechanisms that maintain cellular and organismal functionality.
Both the damage of various cell components and the triggering
of the activation of specific signaling pathways by ROS can influ-
ence numerous cellular processes that have been correlated
with overall longevity in invertebrates and vertebrates (Quarrie
and Riabowol, 2004; Finkel and Holbrook, 2000).
Cells counteract the adverse effects of ROS by upregulating
enzymatic scavengers or DNA-damage repair genes. This
response involves dephosphorylation and subsequent activation
of a small family of ubiquitous transcription factors known as
FoxOs (Liu et al., 2005; Lehtinen et al., 2006; Nemoto and Finkel,
2002). The three FoxO molecules, FoxO1, FoxO3, and FoxO4,
are encoded by different genes, and they all affect differentiation,
proliferation, and survival of a variety of cells including adipo-
cytes, hepatocytes, b cells, myoblasts, thymocytes, and cancer
cells (reviewed in Accili and Arden, 2004; Greer and Brunet,
2005; Arden, 2006; Murakami, 2006). To cite one example, anal-
ysis of mice lacking each of the FoxO proteins in all cells has es-
tablished their role in the resistance of hematopoietic stem cells
to physiologic oxidative stress (Tothova et al., 2007). However,
the potential role of any of the members of this small family of
transcription factors in bone cells has been unknown.
We show here that among the three FoxO proteins, FoxO1 is
the main regulator of redox balance and function in osteoblastsetabolism 11, 147–160, February 3, 2010 ª2010 Elsevier Inc. 147
osteoblasts femur
E
x
p
r
e
s
s
i
o
n
 r
e
l
a
t
i
v
e
 
t
o
 
F
o
x
O
1
FoxO1 FoxO3 FoxO4
A B
6 12
p-FoxO4
months
P Q
D E F
G H I
J
osteoclasts
C
β-actin
LK
6 122
months
Foxo1
M N O
P
E
BM
2
0
0.2
0.4
0.6
0.8
1
1.2
0
0.2
0.4
0.6
0.8
1
1.2
FoxO1 FoxO3 FoxO4
0
0.2
0.4
0.6
0.8
1
1.2
FoxO1 FoxO3 FoxO4
0
0.4
0.8
1.2
0
0.4
0.8
1.2
1.6
6 122
months
Foxo3 Foxo4
0
0.4
0.8
1.2
6 122
months
* #*
p-FoxO1
β-actin
p-FoxO3
β-actin
6 122
R
0.10±0.04 0.11±0.04 0.58±0.21 0.6±0.2 0.2±0.03 1.3±0.210.8±0.2 0.6±0.03 2.3±0.3
6 122
p-FoxO1
/β-actin
p-FoxO3
/β-actin
p-FoxO4
/β-actin
E
x
p
r
e
s
s
i
o
n
 r
e
l
a
t
i
v
e
 
t
o
 
F
o
x
O
1
E
x
p
r
e
s
s
i
o
n
 r
e
l
a
t
i
v
e
 
t
o
 
F
o
x
O
1
E
x
p
r
e
s
s
io
n
 r
e
la
t
i
v
e
 
t
o
 
2
 
m
o
n
t
h
s
E
x
p
r
e
s
s
i
o
n
 r
e
l
a
t
i
v
e
 
t
o
 
2
 
m
o
n
t
h
s
E
x
p
r
e
s
s
i
o
n
 r
e
l
a
t
i
v
e
 
t
o
 
2
 
m
o
n
t
h
s
Figure 1. Expression and Regulation of FoxO Family Members in Bone
(A–C) Expression of all the three FoxO genes in primary calvarial osteoblasts, femurs, and osteoclasts of WT mice by real-time PCR (n = 4 mice/group, and dupli-
cates were performed for cell extracts). Bars indicatemeans ± SEM. Expression levels are relative to FoxO1. FoxO1 expression has been considered 1.Micewere
2 months old.
(D–L) Immunohistochemical localization of FoxO1 in femoral sections of newborn WT mice. (D and G) Images of bone sections depicting FoxO1 staining at
403 and 1003 magnification. (E and H) Sections were counterstained with DAPI. (F and I) FoxO1 and DAPI images were overlaid to visualize nuclear and
cytoplasmic localization of FoxO1 at 403 and 1003 magnification. Arrows indicate representative cells showing nuclear localization of FoxO1 (purple). (J)
DAB staining of FoxO1 in femoral sections. Adjacent sections were stained with FoxO1 and counterstained with (K) eosin or (L) hematoxylin (1003magnification).
P indicates periosteal surface, E indicates endosteal surface, and BM indicates bone marrow. The 1003magnification images are obtained from the endosteal
surface.
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FoxO1-Dependent Redox Balance in Osteoblastsand the only one that overtly controls bone mass. Deletion of
FoxO1 specifically from osteoblasts (Foxo1ob
/ mice)
decreases osteoblast numbers, bone formation rate (BFR), and
bone volume. These effects stem from molecular alterations,
presented below, in both oxidative stress and amino acid import
in the FoxO1 mutant mice; the latter can be reverted by a high-
protein diet (HPD). These observations identify FoxO1 as
a crucial regulator of osteoblast physiology and provide a direct
mechanistic link between oxidative stress and the control of
bone mass.
RESULTS
FoxO1 Is Highly Expressed andRegulated inOsteoblasts
As a first step toward understanding the role, if any, of FoxO
proteins in the skeleton, we studied their pattern of expression
in osteoblasts and osteoclasts. As shown in Figures 1A–1C,
primary osteoblasts as well as whole bone and osteoclasts
express all three FoxO isoforms, with FoxO1 being, by far, the
most abundant member of this family of proteins. To understand
the role of FoxO proteins in skeletogenesis, we first focused on
studying the function they may exert on osteoblasts. Osteo-
blast-specific expression of FoxO1 was confirmed by immuno-
histochemical analysis in bone sections obtained from femurs
of newborn wild-type (WT) mice (Figures 1D–1L). A comparison
between sections stained with FoxO1 (Figures 1D and 1G) and
sections stained with 40,6-diamidino-2-phenylindole (DAPI),
a fluorescent stain that binds strongly to DNA (Figures 1E and
1H), indicated that FoxO1 is expressed in the nucleus of osteo-
blastic cells embedded in the endosteal area of the cortex or
present in the periosteum (Figures 1D–1I). Consistent with the
notion that in the absence of stress stimuli these transcription
factors can shuttle between the nucleus and the cytoplasm,
FoxO1 was also present in the cytoplasm of osteoblasts. The
localization of FoxO1 with respect to the nucleus can be viewed
more clearly by overlaying the images of FoxO1 and DAPI stain-
ing (Figures 1F and 1I). In addition, cytoplasmic and nuclear
localization of FoxO1 was further confirmed in adjacent bone
sections stained for FoxO1 (Figure 1J) and counterstained with
either the cytoplasmic stain eosin (Figure 1K) or the nuclear stain
hematoxylin (Figure 1L).
We next asked whether accumulation or activity of FoxO
proteins was altered with aging or under conditions of increased
oxidative stress. Aging mice fulfill both requirements, as they
show a progressive decrease in bone formation that correlates
with a parallel increase in oxidative stress levels in bone (Almeida
et al., 2007). In this setting, FoxO1 expression progressively
decreased from 2 to 12 months of age, whereas FoxO3 and
FoxO4 levels remained stable in 2-, 6-, and 12-month-old
animals (Figures 1M–1O). Potential changes in the activity of
FoxO1, FoxO3, and FoxO4 were assessed by measuring the
phosphorylation status of Ser256 of FoxO1 and Foxo3 or
Ser193/258 of Foxo4—sites that are phosphorylated by the(M–O) Expression analysis of all the three FoxO isoforms in murine bones collecte
#p < 0.05 (12 months versus 6months). Expression levels are relative to FoxO exp
1. Bars indicate means ± SEM.
(P–R) Activity assessment by phosphorylation status of FoxO1, FoxO3, and FoxO
See also Figures S1 and S2.
Cell Mphosphoinositide 3 (PI3)-kinase/Akt pathway resulting in the
inactivation of FoxO. FoxO1 phosphorylation/inactivation
increased in the bone of agingmice (Figure 1P). FoxO3 activation
status was unaffected by age despite the progressive decrease
in bone formation and the concomitant increase in oxidative
stress (Figure 1Q). Hence, it is unlikely that FoxO3 will be essen-
tial in maintaining bone homeostasis under stressful conditions.
On the other hand, FoxO4 phosphorylation/inactivation
increased progressively in aging animals (Figure 1R). Taken
together, the results of these experiments along with evidence
from several reports identifying the pivotal role of FoxO1 in
angiogenesis, insulin action, organismal growth, and tumorigen-
esis (reviewed in Accili and Arden, 2004) identify FoxO1 as the
best candidate among all FoxO proteins to be involved in osteo-
blast biology. This led us to analyze its function in vivo.
FoxO1 Controls Bone Mass by Acting in Osteoblasts
In view of the results presented above, we generated mice lack-
ing FoxO1 specifically in osteoblasts by crossing a floxed allele
of this gene (Paik et al., 2007; Dacquin et al., 2002) with mice ex-
pressing Cre only in osteoblasts (see Figure S1 available online).
As a control for specificity, we also deleted FoxO3 specifically in
osteoblasts using the same strategy (Figure S2).
FoxO1ob
+/ or FoxO3ob
+/ mice were intercrossed, and
animals homozygous for FoxO1 (FoxO1ob
/) or FoxO3
(FoxO3ob
/) deletion in osteoblasts were obtained. a1(I)
Collagen-Cre-mediated deletion of FoxO1 or FoxO3was specific
to bone and was accompanied by a marked, 75% reduction in
FoxO1 expression in osteoblasts derived from FoxO1ob
/
mice (Figure S1). Similarly, FoxO3 deletion was bone specific,
and its expression levels were reduced by 65% in osteoblasts
from FoxO3ob
/ mice (Figure S2). FoxO1 as well as FoxO3
expression was unaffected in a variety of different tissues exam-
ined, including liver, gut, pancreas, brown and white adipose
tissue, skeletal muscle, and brainstem (Figures S1 and S2).
At 2 months of age, all mutant FoxO1mice had a body weight
similar to that ofWT littermates. In contrast, bonemineral density
(BMD) measured by peripheral dual-energy X-ray absorptiome-
try (DEXA, PIXImus) was decreased in the spine and femur of
both FoxO1ob
+/ and FoxO1ob
/ mice as compared to WT
controls (Figure 2A). At the cellular level, FoxO1ob
/ mice
were characterized by decreased osteoblast numbers (N.Ob./
T.Ar.), bone formation rate (BFR), and bone volume (BV/TV)
(Figure 2B). Cortical thickness in the midshaft femur, although
not statistically significant, was decreased by 11% by FoxO1
deletion in osteoblasts (Figure 2C). Additionally, femoral BV/TV
was decreased by 40%–50%, an effect similar to that observed
in the lumbar verterbrae (Figure 2C). And, although trabecular
bone loss and osteoblast numbers in FoxO1ob
/mice persisted
with age, they did not progress with aging and there were no
age-related changes in their bone phenotype (Figure 2D). Thus,
FoxO1ob
/ mice showed lack of any age-related changes in
their bone phenotype. Loss of FoxO1 expression was stable ind from different ages (n = 4 mice/group). *p < 0.05 (6 months versus 2 months);
ression at 2 months of age. Expression at 2 months of age has been considered
4 in bones collected from mice of different ages.
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Figure 2. Low Bone Formation in FoxO1ob
/ Mice
(A) BMD measured by DEXA in spine and femur of 2-month-old WT, FoxO1ob
+/, and FoxO1ob
/ mice (n = 10 mice/group). *p < 0.05 versus WT.
(B) BV/TV, bone volume over trabecular volume; N.Ob/T.Ar, number of osteoblasts per trabecular area; BFR, bone formation rate, of 2-month-old and OcS/BS,
osteoclast surface per bone surface in verterbrae of 1-month-old WT and FoxO1ob
/ mice (n = 10 mice/group). *p < 0.05 versus WT.
(C) BV/TV in femoral head and midshaft cortical thickness in the femurs of 2-month-old WT and FoxO1ob
/ mice (n = 10 mice/group). *p < 0.05 versus WT.
(D) BV/TV, BFR, and N.Ob/T.Ar in verterbrae of 6- and 12-month-old WT and FoxO1ob
/ mice (n = 5–10 mice/group). *p < 0.05 versus WT.
(E and F) BMD measured by DEXA in spine and femur of 2-month-old WT and FoxO3ob
/ mice (n = 10 mice/group).
(G) Immunoblotting analysis of FoxO4 activity in the bone of WT and FoxO1ob
/ mice.
(H) RT-PCR analysis of FoxO4 expression in osteoblasts transfected with siRNA oligos for FoxO4 or control (Ctrl), scrambled oligos. *p < 0.05 versus control (Ctrl)
siRNA and Ctrl siRNA in OM. OM denotes osteogenic medium.
(I) Proliferation in cultures of osteoblasts transfected with siRNA oligos for FoxO4 or control (Ctrl), scrambled oligos. OM denotes osteogenic medium.
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FoxO1-Dependent Redox Balance in Osteoblaststhe bone of aging FoxO1ob
/ mice (Figure 3C). There was no
statistically significant difference in BFR or any of the other
measured bone parameters between 2-, 6-, and 12-month-old
FoxO1ob
/ mice. In addition, the relative suppression in BFR
between FoxO1ob
/ and WT mice was not statistically signifi-
cant different at 2, 6, or 12 months of age. Finally, bone resorp-
tion increased as indicated by the increase in osteoclast surface
in FoxO1ob
/ as compared to WT control mice (Figure 2B).
There were no age-related changes in the resorption phenotype
of FoxO1ob
/ mice (data not shown). Expression of FoxO3 and
FoxO4 was not affected in the bone of mice with FoxO1 deletion
in osteoblasts (data not shown). Similarly, we found no changes
in FoxO4 activity in the bones of FoxO1ob
/ as compared toWT
control mice (Figure 2G). Thus, the bone phenotypic abnormali-
ties in FoxO1ob
/ mice are independent of changes in the
expression or activity of the other FoxO isoforms.
The effect of FoxO1 deletion in osteoblasts was specific, since
a similar deletion of FoxO3 did not affect BMD in the spine or long
bones of female or male mice (Figures 2E and 2F). Bone volume,
BFR, and osteoblast numbers as well as osteoclast surface were
also not affected in FoxO3ob
/ mice (data not shown). Confirm-
ing the notion that FoxO4 does not regulate bone formation,
siRNA of FoxO4 in osteoblasts (Figure 2H) had no effect on oste-
oblast proliferation as well as on cyclin D1 and D2 and p27Kip1
expression (Figures 2I and 2J). Differentiation was also not
altered by FoxO4 silencing, as evidenced by the lack of an effect
on osteoblast differentiation markers (Figure 2K). These results
support the notion that FoxO1 plays an important and unique
role among all FoxO proteins as a regulator of bone mass.Analysis of Decreased Bone Formation
in FoxO1ob
/ Mice
To elucidate the underlying reason for the low bone formation
phenotype of the FoxO1ob
/ mice, we searched for alterations
in osteoblast function. In vivo analysis of osteoblast proliferation
in FoxO1 mutant mice showed that the decrease in osteoblast
numbers correlated with decreased osteoblast proliferation as
measured by BrdU incorporation (Figures 3A and 3B) in 5.5-
day-old pups. Osteoblast proliferation, expressed either per
trabecular or per bone perimeter, was decreased by approxi-
mately 40% in FoxO1ob
/mice as compared to WT littermates.
Similar to adult mice, FoxO1 is the most abundant of the three
FoxO isoforms in the bone of 5.5-day-old pups, and its inactiva-
tion in FoxO1ob
/ mice at this age has no effect on the expres-
sion levels of FoxO3 or FoxO4 (Figure S1D). FoxOs control cell
cycle through regulation of cyclins D1 and D2 and the cell-cycle
inhibitor p27Kip1 (Arden, 2006). Accordingly, the decline in
osteoblast proliferation was correlated with a decrease in the
expression of cyclin D1 and cyclin D2 and an increase in the
expression of p27kip1 in FoxO1ob
/ bones (Figure 3D). Consis-
tent with the RNA analysis, protein levels of cyclins D1 and D2
decreased in the bone of FoxO1ob
/ mice (Figures 3E and 3F).
Contrasting with the changes in proliferation and expression
of cell-cycle genes, expression of osteoblast differentiation(J) Real-time PCR (RT-PCR) analysis of CyclinD1, D2, and p27Kip1 expression in
(K) RT-PCR analysis of osteoblast differentiation markers in osteoblasts with sile
In all panels, values are means ± SEM.
Cell Mmarkers such as Runx2, bone sialoprotein (Bsp), and type 1
collagenwas not altered in FoxO1ob
/mice (Figure 3G). Expres-
sion of osterix was decreased, suggesting that osterix may be
a target of FoxO1. However, whereas Runx2 protein levels, like
Runx2 RNA, were not affected, protein levels of type I collagen
were decreased in the bone of FoxO1ob
/ mice (Figures 3H
and 3I). In agreement with the lack of changes in the expression
of most osteoblast differentiation markers, calvaria-derived
osteoblastic cells from Foxo1ob
/ mice were able to differen-
tiate as efficiently as WT cells when cultured in osteogenic
medium (Figures 3J and 3K). This was evidenced by normal
expression of Runx2 and alkaline phosphatase (ALP) in primary
osteoblast cultures from FoxO1ob
/ as compared to WT mice.
Finally, we searched for potential effects of FoxO1 deletion on
osteoblast apoptosis. Using TUNEL staining of bone sections,
we found that osteoblast apoptosis is not affected in
FoxO1ob
/mice as compared toWT control animals (Figure 3L).Oxidative Stress Suppresses FoxO1ob
/ Osteoblast
Proliferation
As the first step in elucidating the molecular basis of defective
osteoblast proliferation in FoxO1ob
/ mice, we examined
whether FoxO1 deletion alters redox balance in osteoblasts.
One of the well-described transcriptional targets of the anti-
oxidant properties of FoxO1 is Sod2, the gene encoding the
antioxidant defense enzyme superoxide dismutase 2. Mitochon-
drial SOD2 activity in whole femur extracts was decreased in
Foxo1ob
/ mice (Figure 4A). Consistent with this observation,
the expression of two redox-sensitive genes, Gadd45 and
FasL, was altered. Consistent with the lack of an effect on
osteoblast apoptosis, expression of both the stress-activated
DNA repair gene Gadd45 and the proapoptotic gene FasL
was increased, in the bone of the Foxo1ob
/ mice (Fig-
ure 4B). The expression and activity pattern of FoxO1-regulated
genes indicate a decrease in antioxidant defense responses in
FoxO1ob
/ mice.
More importantly, accumulation of glutathione (GSH), a small
protein with redox-active sulfhydryl moieties which scavenges
and neutralizes ROS, thereby detoxifying cells, was reduced in
the bone of FoxO1ob
/ mice (Figure 4C). The reduction in
GSH levels in FoxO1-deficient osteoblasts should lead to
increased oxidative stress in bone. Indeed, we determined that
production of ROS was increased in osteoblasts from
FoxO1ob
/ mice (Figure 4D). Elevated levels of lipid peroxida-
tion end products, a measure of cellular injury, were also
observed in the bone of FoxO1ob
/ mice (Figure 4E). Taken
together, these results indicate that FoxO1 functions in osteo-
blasts to limit oxidative stress and its deleterious consequences
on the cells.
Two of the most powerful signal transduction pathways acti-
vated by ROS are those involving p53 and p66shc signaling.
Whereas p53 mediates ROS-induced antiproliferative actions
and early senescence or apoptosis, p66shc is an adaptor protein
mediating specifically proapoptotic actions of ROS (Migliaccioosteoblasts with silenced FoxO4.
nced FoxO4.
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Figure 3. Decreased Osteoblast Proliferation in Bones of FoxO1Ob
/ Mice
(A) Sections of femurs from d5.5 WT and FoxO1ob
/ pups stained with BrdU (image, 403 magnification).
(B) Osteoblast proliferation expressed as number of BrdU-stained osteoblasts per trabecular area (T.Ar.) and per bone perimeter (B.Pm) (n = 4 mice/group).
*p < 0.05 versus WT.
(C) RT-PCR analysis of FoxO1, FoxO3, and FoxO4 expression in the bone of WT and FoxO1ob
/mice at indicated ages. d denotes day, and M demotes months
(n = 3 mice per group). *p < 0.05 versus WT; #p < 0.05 versus WT at d5.5; $p < 0.05 versus WT at 1M.
(D) RT-PCR analysis of CyclinD1, D2, and p27Kip1 expression in femurs of WT and FoxO1ob
/ mice at 2 months of age (n = 6 mice/group).
(E and F) Immunoblotting of cyclins D1 and D2 in bones of WT and FoxO1ob
/ mice.
(G) RT-PCR analysis of Runx2, BSP, Osterix, and Col1a1 expression in bones of WT and FoxO1ob
/ mice (n = 6 mice/group). *p < 0.05 versus WT.
(H and I) Immunoblotting of Runx2 and type I collagen in bones of WT and FoxO1ob
/ mice.
(J and K) RT-PCR analysis of Runx2 and Alkaline phosphatase (ALP) expression in cultured primary calvarial osteoblasts of WT and FoxO1ob
/ mice (n = 3)
treated with vehicle or osteogenic medium. *p < 0.05 versus vehicle.
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FoxO1-Dependent Redox Balance in Osteoblastset al., 1999). We found that the activity of p53 and p66shc
increased in bone from FoxO1ob
/ mice (Figures 4F–4H). Two
proteins, the products of p19ARF and p16, activate a p53
pathway which leads to antiproliferative effects (Satyanarayana
and Rudolph, 2004). Thus, consistent with defective osteoblast
proliferation of FoxO1-deficient osteoblasts, and concomitant
with elevated p53 activity, expression of its upstream regulators
p19ARF and p16 increased in osteoblasts from FoxO1ob
/ mice
as compared toWT control animals (Figures 4I and 4J). Similar to
the lack of a bone phenotype in the FoxO3ob
/ mice, these
perturbations were specific of FoxO1 deletion, since expression
of p19ARF and p16 in bone was unaffected by FoxO3 deletion
(Figure 4K). Similarly, knockdown of FoxO4 in osteoblasts had
no effect on Sod2 as well as p19ARF and p16 expression
(Figure S3).
Rescue of the FoxO1ob
/ Phenotype
To determine whether increased oxidative stress in osteoblasts
could be a causative factor for the lowbone formation phenotype
of the FoxO1ob
/ mice, we normalized redox levels by
supplying the antioxidant N-acetyl L-cysteine (NAC). The antiox-
idant actions of NAC are due to its ability to induce either one of
two independent effects: neutralize ROS products by supplying
a pool of amino acids utilized for glutathione synthesis, or block
ROS signaling by suppressing the activity of p53 (Nakamura
et al., 1997; Nogueira et al., 2008). While administration of NAC
had no effect on GSH levels in FoxO1ob
/ mice (Figure 4L), or
on p66shc activity (Figure 4G), it suppressed p53 activity as
well as the expression of p19ARF and p16 (Figures 4F, 4M, and
4N). Consistent with normalization of p53 signaling, NAC
rescued the phenotypic bone abnormalities of FoxO1ob
/
mice such as osteoblast numbers, BFR, and bone volume
(Figure 4O).
To further confirm that the defect in osteoblast proliferation
and the increase in oxidative stress in osteoblasts result from
FoxO1 deficiency, we overexpressed FoxO1 in osteoblasts
derived from FoxO1ob
/ mice. FoxO1 overexpression,
confirmed by RT-PCR and immunoblotting, rescued the
decrease in osteoblast proliferation and, similar to NAC, obvi-
ated the increase in ROS levels, normalized GSH levels, and in-
hibited the increase in p19ARF and p16 expression (Figure S4).
These results demonstrate that increased levels of oxidative
stress in the bone of FoxO1ob
/ mice decrease osteoblast
proliferation by a pathway that controls p19ARF/p16/p53
signaling, thus providing a mechanistic link between pathways
regulating oxidative stress and bone homeostasis under the
control of FoxO1.
Osteoblast FoxO1 Promotes Protein Synthesis
through ATF4
The observations that GSH levels were reduced in the bone of
FoxO1ob
/mice and that NAC administration failed to replenish
them raised the hypothesis that, in addition to activation of p53
signaling presented above, there was also a defect in amino(L) Apoptosis in bone sections from the femurs of 3-month-old WT and FoxO1
apoptotic osteoblasts (right panel).
Control indicates TUNEL staining of a bone section treated with DNase. Magnifica
example of a group of apoptotic osteoblasts. In all panels, values are means ± S
Cell Macid import and protein synthesis in FoxO1-deficient osteo-
blasts. This notion was further supported by the observation
that whereas type I collagen expression was not altered, its
production was decreased in the bone of FoxO1ob
/ mice.
To examine this possibility, we measured the activity of the
translation initiation factor 2 (eIF2), which integrates amino acid
metabolism and resistance to oxidative stress (Harding et al.,
2003). Eukaryotic cells respond to oxidants by phosphorylating
the a subunit of eIF2. In turn, activation of eIF2a initiates the
pathway controlling amino acid import and protection against
oxidative stress (Harding et al., 2002). We found that the phos-
phorylation levels of eIF2a were increased in FoxO1ob
/ osteo-
blasts (Figure 5A), indicating a normal response of eIF2a. Thus,
we reasoned that another component of the protein synthesis
pathway, downstream of eIF2a, may be affected in FoxO1ob
/
osteoblasts. The transcription factor ATF4 is an integral compo-
nent of a negative-feedback pathway controlling amino acid
import, leading to glutathione synthesis, and its expression or
activity is dependent on eIF2a (Harding et al., 2003; Yang
et al., 2004). Although ATF4 mRNA expression remained
unchanged in FoxO1ob
/ bones as compared to WT control
animals (Figure 5B), ATF4 was found to physically associate
with FoxO1 in the nuclei of osteoblasts as well as in bone nuclear
extracts from WT mice (Figures 5C and 5D). Immunohistochem-
ical analysis in bone sections confirmed that FoxO1 and ATF4
colocalize in the nucleus (Figures 5E and 5F). However, both
proteins can also be found in the cytoplasm, as they are known
to shuttle between the two subcellular compartments. In the
absence of any stimuli, in particular stress-related stimulus, the
two transcription factors are predominantly located in the cyto-
plasm. Stress signals stimulate their translocation to the nucleus,
where they actively operate to initiate transcriptional events that
protect cellular functionality.
To examine whether the FoxO1-ATF4 interaction influences
the activity of either of the two transcription factors, we used
COS-7 cells. Cotransfection experiments indicated that ATF4
stimulates FoxO1 activity as measured on a FoxO1 reporter
(Figure 5G). Since osteocalcin is an ATF4 target gene in osteo-
blasts (Yang et al., 2004), activation of ATF4wasmeasured using
a reporter construct that carries 147 bp of the osteocalcin
promoter fused to the Luciferase gene (OG2-Luc). This construct
contains one binding site for ATF4 (Ducy and Karsenty, 1995).
Forced expression of FoxO1, along with ATF4, enhanced the
transactivating ability of ATF4 on OG2-Luc (Figure 5H). These
observations raised the prospect that FoxO1 deletion in osteo-
blasts compromises amino acid synthesis by interfering with
the activity of ATF4. This event leads to a reduction in both
GSH levels and collagen production. Indeed, collagen content
was decreased in the bones of the FoxO1ob
/ mice (Fig-
ure 5I), supporting the notion that protein synthesis by osteo-
blasts is compromised in these animals. Consistent with the
low collagen content, we found a decrease in osteoid surface,
the amount of bone extracellular matrix not mineralized
(Figure 5J). Additionally, a reduction in GSH synthesis will resultob
/ mice (n = 4 mice per group). Arrows indicate osteoblasts (left panel) or
tions are 403 unless otherwise stated. The 1003magnification panel shows an
EM.
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Figure 4. N-Acetyl L-Cysteine Rescues the Increased Oxidative Stress and the Bone Phenotype of FoxO1ob
/ Mice
(A) SOD2 activity in femurs of WT and FoxO1ob
/ mice (u/mg) (n = 6 mice /group). *p < 0.05 versus WT.
(B) RT-PCR analysis of FasL and Gadd45 expression in femurs of WT and FoxO1ob
/ mice (n = 5 mice/group). *p < 0.05 versus WT.
(C) Glutathione (GSH) levels in bones of WT and FoxO1ob
/ mice (n = 5 mice/group). *p < 0.05 versus WT.
(D) Flow cytometry analysis of ROS levels in osteoblasts from bone marrow cells of WT and FoxO1ob
/ mice (n = 5 mice/group). *p < 0.05 versus WT.
(E) Lipid peroxidation levels in bones of WT and FoxO1ob
/ mice (n = 5 mice/group). *p < 0.05 versus WT.
(F and G) p53 and p66shc activity measured by immunoblotting in bones of WT and FoxO1ob
/ mice (n = 2 mice/group).
(H) Densitometric analysis of the ratio of p-p53/p53. ND denotes not determined.
(I and J) RT-PCR analysis of p19ARF and p16 expression in bones of WT and FoxO1ob
/ mice (n = 5 mice/group). *p < 0.05 versus WT.
(K) RT-PCR analysis of p19ARF and p16 expression in bones of WT and FoxO3ob
/ mice (n = 5 mice/group).
(L) GSH levels in osteoblasts of vehicle- or NAC-treated WT and FoxO1ob
/ mice (n = 5 mice/group). *p < 0.05 versus WT vehicle and WT NAC.
(M and N) RT-PCR analysis of p19ARF and p16 expression in bones of vehicle- or NAC-treated WT and FoxO1ob
/mice (n = 5 mice/group). *p < 0.05 versus WT
vehicle; #p < 0.05 versus WT versus FoxO1ob
/ vehicle.
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FoxO1-Dependent Redox Balance in Osteoblastsin a subsequent increase in ROS and oxidative stress. Elevated
ROS do in turn activate p53 signaling.
An implication of this model is that induction of p53 signaling
may be, at least in part, ATF4 dependent. To determine if this
was the case, we measured expression levels of p19ARF and
p16 in Atf4/ osteoblasts. ATF4 deletion increased the expres-
sion of both p53 regulators (Figure 5K), suggesting that the
FoxO1-ATF4 pathway is a determinant of p53 signaling in oste-
oblasts. Collectively, these observations suggest that FoxO1
regulates protein synthesis and oxidative stress in osteoblasts
by interacting with ATF4.
High-Protein Diet Rescues Bone Formation
in FoxO1ob
/ Mice
The finding that FoxO1 is required for protein synthesis in oste-
oblasts and its ability to interact with ATF4 suggested that
a high-protein diet (HPD) could rescue the skeletal manifesta-
tions observed in FoxO1ob
/ mice as it does for the Atf4/
mice (Elefteriou et al., 2006). To test this hypothesis, we used
the same diet that had been used to correct the bone phenotype
of the Atf4/ mice and examined whether it could affect the
bone phenotype of the FoxO1ob
/ mice. WT and FoxO1ob
/
mothers were fed from the first day of gestation with a normal
diet (ND) or a HPD. After weaning, pups were kept on this
same diet up to 28 days of age. At this stage, histomorphometric
analysis showed that HPD fully rescued the low osteoblast
numbers in FoxO1ob
/ mice but had no effect on the increase
in osteoclast surface (Figure 6A). In agreement with these obser-
vations and the notion that osteoblast recruitment is com-
promised in FoxO1ob
/ mice, BV/TV was rescued and BFR,
although not statistically significant, showed a trend toward
partial rescue in HPD-fed FoxO1ob
/ mice (Figure 6A). This
latter effect may indicate that additional pathways, independent
of protein synthesis, may compromise osteoblast function in the
FoxO1ob
/ mice. HPD also normalized the upregulation of p53
activity and the increase in the expression of p19ARF and p16 in
bones of Foxo1ob
/ mice (Figures 6B–6D). Taken together,
these results demonstrate that FoxO1 regulation of osteoblast
proliferation and bone formation occurs mainly through its ability
to favor amino acid import and protein synthesis through inter-
acting with ATF4 and subsequently maintaining redox balance
in osteoblasts.
DISCUSSION
This study reveals that FoxO1 is a major regulator of osteoblast
proliferation and, as a result, of bone homeostasis. The effects of
FoxO1 stem from its ability to maintain redox balance in osteo-
blasts in a p53-dependent manner. FoxO1 also affects osteo-
blast function by regulating amino acid import and thus protein
synthesis. This function results from the physical interaction of
FoxO1 with ATF4, a transcription factor regulating amino acid
import and collagen synthesis by osteoblasts. These results
establish a sequence of molecular events that mediate the
protective effects of FoxO1 in osteoblasts (Figure 7). More(O) BV/TV, N.Ob./T.Ar, and BFR in spines of vehicle or NAC-treated WT and Fo
#p < 0.05 (FoxO1ob
/ NAC versus FoxO1ob
/ vehicle).
In all panels, except (I) and (J), where mice were 5.5 days of age, animals were 3
Cell Mimportant, they provide proof of principle evidence that oxidative
stress does indeed regulate bone mass.
FoxO1, ROS, and Bone Remodeling
The oxidative hypothesis of senescence, since its origin in 1956,
has garnered significant evidence and growing support for the
notion that free radicals play an important role in aging, either
as ‘‘damaging’’ molecules or as signaling molecules. Age-
increasing oxidative injuries induced by free radicals, higher
susceptibility to oxidative stress, genetic manipulations that alter
oxidative resistance, and the antiaging effect of caloric restric-
tion are a few examples documenting the implication of oxidative
stress in the aging process and the development of aging-asso-
ciated diseases. However, to this time, the mechanisms and
mediators that implement the effects of oxidative stress in
different tissues are not completely understood due to the
complex ‘‘network’’ of redox regulatory systems. The identifica-
tion of FoxO1 as a crucial mediator of ROS signaling in osteo-
blasts leads to the delineation of the molecular events that
mediate the effects of oxidative stress on osteoblast proliferation
(Figure 7). Our observations that (1) FoxO1 interacts with ATF4
and that this interaction promotes both FoxO1 and ATF4 activity,
(2) protein synthesis is compromised in osteoblasts from
Foxo1ob
/ mice, and (3) HPD rescues the low bone formation
phenotype of Foxo1ob
/ mice indicate that FoxO1 controls
osteoblast proliferation by interacting with ATF4 and promoting
protein synthesis.
p19/p16/p53 Signaling Mediates FoxO1’s Antioxidant
Properties
Increased levels of ROS and lipid peroxidation products and
activation of a stress-evoked, p53-dependent signaling cascade
were observed in the bones of Foxo1ob
/ mice. Administration
of the antioxidant NAC rescues the low bone formation pheno-
type of Foxo1ob
/ mice and restores redox balance in FoxO1-
deficient osteoblasts. These studies reveal that FoxO1 in osteo-
blasts organizes antioxidant responses in a mechanism that
involves inhibition of p53-dependent signaling. This is particu-
larly important for the biology of FoxO1 action in antioxidant
defense, which to this time had identified only Sod2, catalase,
Gadd45, Bim, and FasL as the direct transcriptional targets of
FoxO1 during stress (Lehtinen et al., 2006). In our hands, HPD,
along with rescuing the bone phenotype of Foxo1ob
/ mice,
also suppresses p53 signaling in bone, thus indicating that
protein synthesis is required for redox balance in osteoblasts.
Thus, FoxO1 controls osteoblast proliferation by actions that
involve interaction with ATF4, and downstream regulation
of a stress-dependent pathway that controls p53 signaling
(Figure 7).
FoxO1 and Insulin/IGF-1 Signaling
We have found that FoxO1ob
/ mice have a metabolic pheno-
type characterized by improved glucose tolerance and insulin
sensitivity and increased insulin secretion, secondary to an
increase in b cell proliferation (Rached et al., 2010). Thus, it isxO1ob
/ mice (n = 5 mice/group). *p < 0.05 (FoxO1ob
/ vehicle versus WT);
months of age; values are means ± SEM. See also Figures S3 and S4.
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Figure 5. Altered Amino Acid Metabolism in Osteoblasts of FoxO1ob
/ Mice
(A) Immunoblotting analysis of the phosphorylation status of eIF2a in bone from WT and FoxO1ob
/ mice (n = 5 mice/group).
(B) RT-PCR analysis of ATF4 expression in bone from WT and FoxO1ob
/ mice (n = 5 mice/group).
(C and D) Immumoprecipitation (IP) and immunoblotting of FoxO1 and ATF4 in nuclear extracts from primary osteoblasts and bones of WT mice.
(E) Immunohistochemical localization of FoxO1 and ATF4 in femoral sections of newborn, WT mice. Shown are images of bone sections depicting FoxO1, ATF4,
DAPI, and combination of ATF4 with DAPI or FoxO1 with ATF4 stainings. The top five panels show 403 and the five lower panels show 1003 magnifications.
P indicates periosteal surface, E indicates endosteal surface, and BM indicates bone marrow. The 1003magnification images are obtained from the endosteal
surface.
(F) Immunohistochemical localization of FoxO1 and ATF4 in primary osteoblasts. Single-cell images at 1003magnification show staining with the indicated anti-
bodies.
(G) Cotransfection of FoxO1, ATF4, and FoxO-Luc reporter construct in COS-7 cells. EV denotes empty vector. Results are presented as fold induction over EV.
(EV = 1). *p < 0.05 versusFoxO-luc; #p < 0.05 versus FoxO1/FoxO-luc.
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Figure 6. High-Protein Diet Rescues the
Bone Phenotype of FoxO1ob
/ Mice
(A) BV/TV, N.Ob/T.Ar., BFR, and osteoclast
surface in the verterbrae of WT and FoxO1ob
/
on ND or HPD (n = 5 mice/group). *p < 0.05
(FoxO1ob
/ ND versus WT ND); #p < 0.05
(FoxO1ob
/ HPD versus FoxO1ob
/ ND). The
OcS/BS data shown for WT and FoxO1ob
/
mice on ND are identical to those shown in
Figure 2B.
(B) Immunoblotting of phospho-p53 in bones of
WT and FoxO1ob
/ on ND or HPD.
(C and D) RT-PCR analysis of p19ARF and p16
expression in bones of WT and FoxO1ob
/ on
ND or HPD (n = 5 mice/group). *p < 0.05
(FoxO1ob
/ versus WT); #p < 0.05 (FoxO1ob
/
HPD versus FoxO1ob
/ ND).
In all panels, mice were 1 month of age, and in (A),
(C), and (D), values or bars indicate means ± SEM.
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FoxO1-Dependent Redox Balance in Osteoblastspossible that increased insulin levels in the FoxO1ob
/micemay
affect osteoblast proliferation. In addition to insulin, IGF-1
signaling suppresses FoxO activity and is known to promote
osteoblast function (Zhang et al., 2002). However, we have found
that proliferation is decreased in ex vivo cultures of osteoblasts
obtained from FoxO1ob
/ mice as compared to WT littermates
(data not shown), suggesting that an intrinsic factor is not the
main cause for the low osteoblast numbers. These observations,
along with a plethora of evidence in the literature that FoxO1 is
the main mediator of insulin actions (Accili and Arden, 2004),
suggest that the defect in osteoblast proliferation and its rescue
with HPD is most likely independent of changes in insulin levels.
However, further gene inactivation experiments will be required
to obtain a definitive answer.
Osteoblasts Lacking FoxO1 Show Decreased Collagen
Content but Intact Mineralization
We have found that although Osterix expression was sup-
pressed by FoxO1 deletion, osteoblast differentiation was not(H) Cotransfection of FoxO1, ATF4, and OG2-Luc reporter construct in COS-7 cells. EV denotes empty vecto
(EV = 1). *p < 0.05 versus OG2-luc; #p < 0.05 versus ATF4/OG2-Luc and versus FoxO1/OG2-luc).
(I) von Gieson staining indicating collagen content (stained red) on vertebral sections from 2-, 6-, and 12-mo
results from n = 5 mice per group.
(J) Osteoid surface by von Kossa staining in vertebral sections from 1-month-old WT and FoxO1ob
/ mice
surface and bone surface, respectively. Arrows indicate osteoid deposition. *p < 0.05 versus WT.
(K) RT-PCR analysis of p19ARF and p16 expression in primary osteoblasts derived from Atf4/ mice. *p < 0
In all panels, values are means ± SEM.
Cell Metabolism 11, 147–160overtly affected as determined by the
lack of changes in the expression of Alp
and Bsp in the bone and in ex vivo
cultures of osteoblasts from FoxO1ob
/
mice. However, as reported for ATF4/
mice (Yang et al., 2004), type I collagen
expression is not affected, but its syn-
thesis and bone collagen content are
decreased in the FoxO1ob
/ mice, sup-
porting the notion that protein synthesis
by osteoblasts is compromised in these
animals. Consistent with the low collagencontent, we found a decrease in osteoid surface, the amount of
bone extracellular matrix not mineralized. However, because Alp
expression is not affected and serum calcium and phosphate
levels are normal in the serum of FoxO1ob
/ mice (data not
shown), mineralization appears to be overall unaffected in
FoxO1ob
/ mice.
The Role of Broadly Expressed Transcription Factors
in Osteoblast Function
Until recently, the prevailing view of the transcriptional control of
osteoblast biology was that it involves one of three proteins that
are expressed specifically in osteoblasts: Runx2, Osterix, and/or
ATF4. However, FoxO1 has a potent effect on bone formation in
spite of its ubiquitous expression. The paradigm of FoxO1 action
on osteoblast adds to the growing list of broadly expressed
proteins and transcription factors that are found to be crucial
for the control of bone remodeling. LRP5 is now recognized to
control bone formation by inhibiting serotonin synthesis in the
duodenum (Yadav et al., 2008). CREB, another ubiquitousr. Results are presented as fold induction over EV.
nth-old WT and FoxO1ob
/ mice . Representative
(n = 6 mice per group). OS and BS denote osteoid
.05 versus WT.
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Figure 7. Model Depicting the Mechanism of FoxO1 Action in
Osteoblasts
Under physiological levels of stress, FoxO1 shuttles between the nucleus and
the cytoplasm. In the nucleus, FoxO1 interacts with ATF4. This interaction
promotes the transcriptional activity of FoxO1 and is required for amino acid
import and protein synthesis. Normal protein synthesis allows FoxO1 to
orchestrate an antioxidant defense mechanism that maintains redox balance
by suppressing expression of p19ARF and p16 and downstream activation of
their target protein p53. Transcriptional repression of the p19ARF/p16/p53
pathway prevents cell-cycle arrest in osteoblasts and maintains their normal
proliferation and bone homeostasis.
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FoxO1-Dependent Redox Balance in Osteoblaststranscription factor, is a transcriptional effector of serotonin
action on bone (Yadav et al., 2008). Schnurri-3, mostly known
for its functions as an adaptor protein in the immune system, is
an important regulator of adult bone formation (Jones et al.,
2006). And the broadly expressed AP-1 family members (Fos/
Jun) have an essential role in bone development and bone forma-
tion (Wagner, 2002; Fu et al., 2005). These observations suggest
that in addition to the osteoblast-specific transcription factors,
ubiquitously expressed ones can also influence the function of
these cells. Whether this is achieved by means of interaction
with the osteoblast-specific proteins or by means of activating
novel signaling cascades (such as FoxO1) remains to be exam-
ined. In any case, the transition from a broadly expressed protein
to a tissue-specific pathway highlights the importance of the
crosstalk betweendifferent organs and illustrates the importance
of an integrative approach to bone physiology.EXPERIMENTAL PROCEDURES
Generation of Mutant Mice
All the protocols and animal treatment procedures described have been
approved by the Institute of Comparative Medicine, Columbia University.
FoxO1Ob
/ and FoxO3Ob
/ were generated by crossing a1(I)Collagen-Cre
mice with FoxO1 or FoxO3 floxed mice that have been previously described
(Paik et al., 2007; Dacquin et al., 2002). In all experiments, littermates of
FoxO1ob
/ mice were used as WT control animals. Those mice were homo-
zygous for the floxed FoxO1 allele.158 Cell Metabolism 11, 147–160, February 3, 2010 ª2010 Elsevier InAnimal Treatments
N-acetyl-l cysteine (Sigma) was administrated i.p., 50 mg/kg twice a day for
3 weeks (Almeida et al., 2007). 13 PBS was given to sham mice. ND and
HPD were obtained from Harlan Teklad (USA). The HPD contained 50%
protein, 31.6% carbohydrate, and 5.5% fat. The ND contained 20.3% protein,
61.6% carbohydrate, and 5.5% fat. They are matched for calcium (0.7%) and
phosphorus (0.54%) content. For all animal experiments, littermates were
used as WT control animals. Genotyping was performed at 3 weeks of age
by PCR analysis of genomic DNA.
Histology, Protein Expression, and Proliferation Assays
Immunohistochemistry was performed according to standard protocols on un-
decalcified specimens embedded in paraffin and sectioned at 5 mm. Immune
complexes were visualized using anti-FOXO1 (Cell Signaling) or anti-ATF4
(Santa Cruz). FoxO1 and ATF4 were visualized with CY3-conjugated (red)
and CY2-conjugated (green) secondary antibodies (Jackson Immuno-
Research), respectively. Sections were counterstained with DAPI to visualize
the cell nuclei (blue). Alternatively, FoxO1 expression was detected using the
stable chromogen DAB (Diaminobenzidine) and counterstaining with hema-
toxylin or eosin. Images were acquired with a Nikon 80i Eclipse Microscope
using a Retiga digital camera. Osteoblast or bone extracts (50–80 mg) from
WT and FoxO1ob
/ mice were anayzed on a SDS-polyacrylamide gel, trans-
ferred to a PVDF membrane, and probed with the appropriate antibodies.
Immunoblotting primary antibodies were against total or Phospho-p66Shc
(BD Biosciences), phospho-FoxO1, phospho-FoxO3, phospho-FoxO4, phos-
pho-53 and eIF2a (Cell Signaling, Beverly, MA), and FoxO1, FoxO3, and
FoxO4 (Santa Cruz). Antibodies against b-actin and Lamin B1 were obtained
from Santa Cruz. The intensity of the bands was measured by densitometry
(Image J software). The ratios of phospho to total proteins was calculated
based on the intensity of the bands determined by densitometry. In vivo oste-
oblast proliferation assays (Zymed Laboratories) were performed on femurs of
d5.5 mice pups injected with BrdU (0.4 mg) and sacrificed 4 hr later. In vitro
osteoblast proliferation was assessed using the CellTiter One System (Prom-
ega) according to the manufacturer’s instructions. Static and dynamic histo-
morphometric analyses were performed on vertebral column specimens
collected from 1-, 2-, 3-, 6-, and 12-month-old mice using undecalcified
sections according to standard protocols using the osteomeasure analysis
system (Osteometrics). Type I collagen content was analyzed by von Gieson
staining in undecalcified sections. Analysis of BMD was performed as previ-
ously described (Kousteni et al., 2002). Six to twelve animals were analyzed
for each group.
Cell Culture and Treatments
Calvaria-derived primary osteoblastic cells from WT and FoxO1ob
/ mice
were plated in aMEM medium containing 1% FBS. Treatments with NAC
were performed at 2 mM. Differentiation to the osteogenic lineage was
induced in osteogenic medium containing 50 mM ascorbic acid and 50 mM
b-glycerol phosphate. Cotranfection was carried out in COS-7 cells as
described previously (Kousteni et al., 2001). Renilla luciferase control vector
(Promega) was cotransfected as an internal standard to normalize for transfec-
tion efficiency. Normalized luciferase activity is presented as fold induction
over the empty vector control (EV, considered 1).
Biochemical Studies
Intracellular ROS levels weremeasured in BMcells bymeans of flow cytometry
using an oxidation sensitive fluorescent probe dye, 20,70-dichlorodihydrofluor-
escin diacetate (H2DCFDA). BM cells flushed from femurs were incubated with
goat anti-mouse Osteocalcin (OCN) antibody for 20 min at 4C followed by
incubation with donkey anti-goat Alexa 680 secondary antibody for 20 min
at 4C. After two washes, cells were incubated with 10 mM H2DCFDA for
30 min at 37C, and fluorescence was measured using an LSR II flow cytom-
eter (BD Biosciences). Osteoblastic cells were identified as a CD45low, OCN+
population. OCN+ cells were first gated, and the mean fluorescence intensity
(MFI) of the DCF is measured. Analysis was performed using FloJo software
(TreeStar). Lipid peroxidation end product (4-hydroxy-2[E] nonenal: 4-HNE +
malondialdehyde: MDA) levels were measured in femurs by using lipid perox-
idation assay kit (Calbiochem, San Diego, CA). The levels of 4-HNE + MDA
were determined from standard calibration curve constructed using MDAc.
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mmol 4-HNE+MDA/mg protein. Reduced glutathione levels in the tibia extracts
were measured by the 5,50-dithiobis-2-nitrobenzoic acid-glutathione disulfide
reductase recycling method as described previously (Rahman et al., 2006).
Mitochondrial superoxide dismutase (SOD-2) activity was measured in femurs
using Superoxide Dismutase Assay Kit II (Calbiochem).
Molecular Studies
RNA isolation and real-time PCR were performed following standard proto-
cols. Primer sequences are shown in Table S1.
siRNA Knockdown
Primary osteoblasts were transfected with the FoxO4 siRNA oligos or control
scrambled siRNA oligos (Santa Cruz) using siRNA transfection reagents (Santa
Cruz) as described by the manufacturer.
Adenoviral Infection
High-titer virus stocks were produced by infecting FoxO1 and EV adenoviral
expression vectors into HEK293- based packaging cell line. After 72 hr, virus
was collected and viral titer was determined. Calvaria-derived osteoblastic
cells were infectedwith FoxO1 or EV control adenoviral constructs. Forty-eight
hours later, cells were harvested and used for different assays.
Apoptosis in Bone Sections
Apoptosis was assessed in decalcified, paraffin-embedded femoral sections
from 3-month-old WT and FoxO1ob
/ mice using the DeadEnd Colorimetric
TUNEL System (Promega) according to the manufacturer’s instructions.
Apoptotic osteoblasts and total osteoblasts were counted, and the per-
centage of apoptotic cells was calculated.
Statistical Analysis
Results are given asmeans ± standard deviations from themean (SEM). Statis-
tical analysis was performed by Student’s t test where p < 0.05 is considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at doi:10.1016/j.cmet.2010.01.001.
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